Facebook grupa Dividend Kingdom
Hej wszystkim ponownie, tydzień temu wrzuciłem posta o bardzo znanej i szanowanej w świecie dywidendowym – AbbVie. Dzisiaj tak jak zapowiadałem, przyszedł czas na następną spółkę Bristol-Myers Squibb (BMY: NYSE), którą posiadam w portfelu. Spółka ta w moim przekonaniu jest:
- niedowartościowana
- oferuje przyzwoitą i niezagrożoną dywidendę
- najwyższy potencjał wzrostu na najbliższe lata względem np. ABBV, Merck, Pfizer, można wręcz powiedzieć, że BMY jest to growth stock z dywidendą, albo spółka dywidendowa o potencjale wzrostowej
- bezpieczna, bardzo duża dywersyfikacja udziału poszczególnych leków w zysku firmy
Bristol-Myers Squibb (BMY: NYSE)
Amerykańska firma bio-farmaceutyczna założona w 1989 roku, mająca siedzibę w Nowym Jorku. Obecnie lider w leczeniu raka na świecie. Firma specjalizuje się w produkcji leków na receptę w kilku obszarach:
- rak
- HIV/AIDS
- choroba sercowo-naczyniowa
- cukrzyca
- zapalenie wątroby
- reumatoidalne zapalenie stawów
- zaburzenia psychiczne
Ostatnie istotne działania firmy:
- Przejęcie firmy Celegne w 2019 roku za 74mld $ (największa farmaceutyczne przejęcie w historii), tworząc największą firmę zajmującą się leczeniem raka na świecie!
- zwiększenie portfela onkologicznego i możliwość produkcji leków na raka krwi Revlimid i Imnovid
- przejęcie MyoKardia w 2020 roku za 13,1mld $
- zwiększenie portfela Kardiologicznego i złożenie aplikacji do FDA o zaakceptowane Mavacamten leku na objawowe HCM
- złożenie do FDA aplikacji leku Ide-cel na nowotwór układu krwiotwórczego (szpiczak mnogi), decyzja o akceptacji ma zapaść w Marcu 2021, według analityków Wallstreet będzie to najważniejsza decyzja w kwestii dopuszczenia jakiegokolwiek leku w tym roku!
Portfel:
Zysk 10,54 mld $ za 3Q 2020, względem 6 mld $ za 3Q 2019, 75% wzrost zysków (nie ujmując zysków Celegne w 2019 kiedy nie była częścią BMY, jeśli ująć to wzrost zysku o 6%)
EPS wzrost spadek o 1% z 0,83 do 0,82
Non-GAAP Diluted EPS wzrost o 39%, z 1,17 do 1,63
Onkologiczny:
Revlimid – 3,03 mld $, wzrost 10% r/r (najlepiej sprzedający się lek)
Opdivo – 1,78 mld $, wzrost 2% r/r
Imnovid – 777 mln $, wzrost 17% r/r
Sprycel – 544 mln $, wzrost 3% r/r
Yervoy – 446 mln $, wzrost 26% r/r
Abraxane – 342 mln $
Empliciti – 96 mln $
Reblozyl – 96 mln $
Zeposia – 2 mln $
Onureg – 2 mln $
Kardiologiczny:
Eliquis – 2,1 mld $, wzrost 9% r/r
“Przeciwreumatyczny”:
Orencia – 826 mln $, wzrost 8% r/r
Perspektywy na przyszłość:
- leki Eliquis (3), Opdivo (4), Revlimid (7) są na liście top 10 najlepszych sprzedających się leków do 2025 roku na świecie
- Eliquis, Orencia i Yervoy sprzedają się coraz szybciej z roku na rok, dodatkowo przejęcie Celegne umożliwiło pozyskanie najlepiej sprzedającego się leku Revlimid i kolejnego ze świetnym tempem wzrostu Imnovid (patrzcie wzrosty w punkcie „portfel”)
- w marcu 2021 ma być decyzja FDA o dopuszczeniu leku Ide-cel (według analityków najważniejsza decyzja FDA tego roku w całym sektorze)
- Analitycy Wallstreet prognozują średni roczny wzrost zysków na poziomie 21% przez następne 5 lat
Ryzyka:
- możliwa w marcu 2021 negatywna decyzja FDA o dopuszczeniu leku Ide-cel
- w 2022 roku wejdą generyki od konkurencji dla najlepiej sprzedającego się obecnie leku Revlimid
- zaciągnięte długi na przejęcie Celegne, podobnie jak w przypadku ABBV, pozytywny FCF i jego wzrost sprawia, że jest on problemem tymczasowym, który zostanie rozwiązany
Fundamenty:
Wartość rynkowa = 141 mld $
Forward P/E = 8,25
P/E = N/A bo przejęcie Celegne
PEG 5 letni = 0,5
Altman-Z = 2,06 (gurufocus grey zone)
Wzrost FCF = 31%
Wzrost wartości księgowej = 17%
Dywidenda:
Yield = 3,14% (ex div zakończył się 31 grudnia 2020, płatność 1 lutego 2021)
Payout = 29%
Lat płatności dywidendy = 13
Źródła: www.bms.com, gurufocus.com, seekingalpha.com, motleyfool.com
[PF]
Powyższy opis ma charakter edukacyjny, nie jest rekomendacją.
Bristol - Myers Squibb Company NYSE: BMY p. farmaceutyczny m.in. leki na raka
Re: Bristol - Myers Squibb Company NYSE: BMY p. farmaceutyczny m.in. leki na raka
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!
REKLAMA
Re: Bristol - Myers Squibb Company NYSE: BMY p. farmaceutyczny m.in. leki na raka
EPS / Forecast
1.46 / 1.41
Revenue / Forecast
11.07B / 10.72B
1.46 / 1.41
Revenue / Forecast
11.07B / 10.72B
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!
Re: Bristol - Myers Squibb Company NYSE: BMY p. farmaceutyczny m.in. leki na raka
Is Bristol-Myers Squibb undervalued right now?
https://youtu.be/SN-Lw9bgAhw
https://youtu.be/SN-Lw9bgAhw
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!
Re: Bristol - Myers Squibb Company NYSE: BMY p. farmaceutyczny m.in. leki na raka
EPS / Forecast
1.74/ 1.81
Revenue / Forecast
11.07B / 11.12B
1.74/ 1.81
Revenue / Forecast
11.07B / 11.12B
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!
Re: Bristol - Myers Squibb Company NYSE: BMY p. farmaceutyczny m.in. leki na raka
Kiedy Bristol Myers Squibb kupił biotechnologiczną firmę Celgene za 80 miliardów dolarów pod koniec 2019 roku, dołączył do tego dodatkową ofertę: Jeśli trzy eksperymentalne terapie Celgene uzyskałyby zatwierdzenie Food and Drug Administration na czas, Bristol zapłaciłby dodatkowe 9 dolarów za akcję, w sumie ponad 6 miliardów dolarów.
https://www.paszport.ws//akcjonariusze- ... -z-celgene
https://www.paszport.ws//akcjonariusze- ... -z-celgene
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!
Re: Bristol - Myers Squibb Company NYSE: BMY p. farmaceutyczny m.in. leki na raka
Undervalued Dividend Growth Stock of the Week: Bristol-Myers Squibb (BMY)10.01.2021
Undervalued Dividend Growth Stock of the Week: Bristol-Myers Squibb (BMY)
https://dailytradealert.com/2021/01/10/ ... quibb-bmy/
https://www.youtube.com/watch?v=WPBmahh ... sAndIncome
by Jason Fieber, Mr. Free at 33 • June 6, 2021
https://dailytradealert.com/2021/06/06/ ... ibb-bmy-2/
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!
Re: Bristol - Myers Squibb Company NYSE: BMY p. farmaceutyczny m.in. leki na raka
Which is a Better Investment? Amgen vs Bristol-Myers Squibb... the Winner May Surprise You
https://www.youtube.com/watch?v=1ThVdclIbtY
https://www.youtube.com/watch?v=1ThVdclIbtY
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!
Re: Bristol - Myers Squibb Company NYSE: BMY p. farmaceutyczny m.in. leki na raka
Latest Release
Jul 28, 2021
EPS / Forecast
1.93 / 1.89
Revenue / Forecast
11.7B / 11.29B
Jul 28, 2021
EPS / Forecast
1.93 / 1.89
Revenue / Forecast
11.7B / 11.29B
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!
Re: Bristol - Myers Squibb Company NYSE: BMY p. farmaceutyczny m.in. leki na raka
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!
Re: Bristol - Myers Squibb Company NYSE: BMY p. farmaceutyczny m.in. leki na raka
Latest Release
Oct 27, 2021
EPS / Forecast
2 / 1.93
Revenue / Forecast
11.62B / 11.62B
Bristol Myers reports 10% quarterly sales growth as cancer drugs rebound
(Reuters) - Bristol Myers (NYSE:BMY) Squibb Co on Wednesday said its third-quarter sales rose 10% and reported higher-than-expected earnings as its core cancer business regained momentum after a decline earlier this year.
The New York-based drugmaker's revenue for the quarter of $11.6 billion and adjusted profit of $2.00 per share both topped Wall Street estimates of $11.58 billion in sales and $1.92 per share, according to IBES data from Refinitiv.
Bristol Myers raised the low end of its full-year adjusted profit forecast by 5 cents and now expects to earn $7.40 to $7.55 per share.
Bristol Myers had missed analysts' estimates in the first quarter, largely due to a decline in sales of its growth driver, the cancer immunotherapy Opdivo.
Sales growth has since recovered even as the Delta variant of the coronavirus caused a surge in global COVID-19 cases that could have kept people from seeking treatment for other diseases.
"We're seeing good recovery from COVID really across all of our markets," Chris Boerner, Bristol Myers' chief commercialization officer, said in an interview.
"In immuno-oncology, we've seen a gradual recovery in patient volume," he added. "We're still about 5 to 10% below where we were pre-COVID, but the trend is moving in the right direction."
Cancer drugs Revlimid and Opdivo generated sales of more than $3.3 billion and $1.9 billion respectively. The blood thinner Eliquis, which Bristol shares with Pfizer Inc (NYSE:PFE), brought in more than $2.4 billion. All three were higher than sales reported a year earlier.
The drugmaker is continuing to look at expanding its pipeline of medicines in development through deals, mostly involving smaller, early-stage companies in areas such as cancer, immunology, and cardiovascular health, Chief Financial Officer David Elkins said.
Bloomberg News reported last week that Bristol Myers has expressed interest in buying autoimmune disease drug developer Aurinia Pharmaceuticals (NASDAQ:AUPH) Inc, citing people familiar with the matter.
Oct 27, 2021
EPS / Forecast
2 / 1.93
Revenue / Forecast
11.62B / 11.62B
Bristol Myers reports 10% quarterly sales growth as cancer drugs rebound
(Reuters) - Bristol Myers (NYSE:BMY) Squibb Co on Wednesday said its third-quarter sales rose 10% and reported higher-than-expected earnings as its core cancer business regained momentum after a decline earlier this year.
The New York-based drugmaker's revenue for the quarter of $11.6 billion and adjusted profit of $2.00 per share both topped Wall Street estimates of $11.58 billion in sales and $1.92 per share, according to IBES data from Refinitiv.
Bristol Myers raised the low end of its full-year adjusted profit forecast by 5 cents and now expects to earn $7.40 to $7.55 per share.
Bristol Myers had missed analysts' estimates in the first quarter, largely due to a decline in sales of its growth driver, the cancer immunotherapy Opdivo.
Sales growth has since recovered even as the Delta variant of the coronavirus caused a surge in global COVID-19 cases that could have kept people from seeking treatment for other diseases.
"We're seeing good recovery from COVID really across all of our markets," Chris Boerner, Bristol Myers' chief commercialization officer, said in an interview.
"In immuno-oncology, we've seen a gradual recovery in patient volume," he added. "We're still about 5 to 10% below where we were pre-COVID, but the trend is moving in the right direction."
Cancer drugs Revlimid and Opdivo generated sales of more than $3.3 billion and $1.9 billion respectively. The blood thinner Eliquis, which Bristol shares with Pfizer Inc (NYSE:PFE), brought in more than $2.4 billion. All three were higher than sales reported a year earlier.
The drugmaker is continuing to look at expanding its pipeline of medicines in development through deals, mostly involving smaller, early-stage companies in areas such as cancer, immunology, and cardiovascular health, Chief Financial Officer David Elkins said.
Bloomberg News reported last week that Bristol Myers has expressed interest in buying autoimmune disease drug developer Aurinia Pharmaceuticals (NASDAQ:AUPH) Inc, citing people familiar with the matter.
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!
Re: Bristol - Myers Squibb Company NYSE: BMY p. farmaceutyczny m.in. leki na raka
Undervalued Dividend Growth Stock of the Week: Bristol-Myers Squibb (BMY)Undervalued Dividend Growth Stock of the Week: Bristol-Myers Squibb (BMY)10.01.2021
Undervalued Dividend Growth Stock of the Week: Bristol-Myers Squibb (BMY)
https://dailytradealert.com/2021/01/10/ ... quibb-bmy/
https://www.youtube.com/watch?v=WPBmahh ... sAndIncome
by Jason Fieber, Mr. Free at 33 • June 6, 2021
https://dailytradealert.com/2021/06/06/ ... ibb-bmy-2/
by Jason Fieber, Mr. Free at 33 • December 19, 2021
https://dailytradealert.com/2021/12/19/ ... ibb-bmy-3/
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!
Re: Bristol - Myers Squibb Company NYSE: BMY p. farmaceutyczny m.in. leki na raka
Bristol Myers Squibb (BMY) jumped nearly 4%, helped by news of a $5 billion share buyback. It is in buy range from the 62.77 buy point of a cup-with-handle base.
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!
Re: Bristol - Myers Squibb Company NYSE: BMY p. farmaceutyczny m.in. leki na raka
This Blue-Chip Dividend Growth Stock is Too Cheap to Ignore
by Chuck Carnevale of FAST Graphs • October 8, 2022
A+ rated Bristol Myers Squibb (BMY) is a blue-chip dividend growth stock offering a 3% and growing current yield. Historically, this stalwart pharmaceutical giant has commanded a premium valuation multiple by Mr. Market.
However, since November 2018 Bristol Myers has been selling at a discount to not only its historical norms but historical market norms as well. Despite this low valuation, the company has outperformed the S&P 500 on both dividend income and capital appreciation.
Furthermore, this low valuation also supports an opportunity for outsized future gains at below-average levels of risk. In addition to the company’s extremely high quality, the significant undervaluation provides a margin of safety as an additional layer of risk mitigation.
https://dailytradealert.com/2022/10/08/ ... to-ignore/
by Chuck Carnevale of FAST Graphs • October 8, 2022
A+ rated Bristol Myers Squibb (BMY) is a blue-chip dividend growth stock offering a 3% and growing current yield. Historically, this stalwart pharmaceutical giant has commanded a premium valuation multiple by Mr. Market.
However, since November 2018 Bristol Myers has been selling at a discount to not only its historical norms but historical market norms as well. Despite this low valuation, the company has outperformed the S&P 500 on both dividend income and capital appreciation.
Furthermore, this low valuation also supports an opportunity for outsized future gains at below-average levels of risk. In addition to the company’s extremely high quality, the significant undervaluation provides a margin of safety as an additional layer of risk mitigation.
https://dailytradealert.com/2022/10/08/ ... to-ignore/
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!
Re: Bristol - Myers Squibb Company NYSE: BMY p. farmaceutyczny m.in. leki na raka
Latest Release
Feb 02, 2023
EPS / Forecast
1.82 / 1.73
Revenue / Forecast
11.4B / 11.21B
Feb 02, 2023
EPS / Forecast
1.82 / 1.73
Revenue / Forecast
11.4B / 11.21B
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!
Re: Bristol - Myers Squibb Company NYSE: BMY p. farmaceutyczny m.in. leki na raka
(Reuters) -Bristol Myers Squibb Co said on Wednesday CEO Giovanni Caforio will step down in November and be succeeded by Chief Commercialization Officer Christopher Boerner.
Boerner, who has been CCO since 2018, was named chief operating officer until he takes the top job. He joined the company in 2015 and previously served in leadership roles at Seattle Genetics (NASDAQ:SGEN) Inc and Roche's Genentech.
Boerner said he is aligned with Caforio on the direction for the company.
"We have a very strong foundation as a company and Giovanni and I are going to continue to work together to deliver on that value," Boerner said in an interview.
Caforio, who has been CEO since 2015, will remain as executive chairman of the company's board.
"It's really the right time for me to step back and spend time with my family, who are in Europe. That's really the main driver of the decision" to retire, Caforio, 58, said in an interview.
Under Caforio's tenure, Bristol Myers (NYSE:BMY) bought Celgene (NASDAQ:CELG) for $74 billion in 2019, boosting its revenue as sales of its top-selling cancer drug Opdivo slowed due to stiff competition from Merck & Co Inc's Keytruda.
Bristol Myers also named Adam Lenkowsky as chief commercialization officer, replacing Boerner.
Bristol Myers is due to report first-quarter financial results on Thursday.
Boerner, who has been CCO since 2018, was named chief operating officer until he takes the top job. He joined the company in 2015 and previously served in leadership roles at Seattle Genetics (NASDAQ:SGEN) Inc and Roche's Genentech.
Boerner said he is aligned with Caforio on the direction for the company.
"We have a very strong foundation as a company and Giovanni and I are going to continue to work together to deliver on that value," Boerner said in an interview.
Caforio, who has been CEO since 2015, will remain as executive chairman of the company's board.
"It's really the right time for me to step back and spend time with my family, who are in Europe. That's really the main driver of the decision" to retire, Caforio, 58, said in an interview.
Under Caforio's tenure, Bristol Myers (NYSE:BMY) bought Celgene (NASDAQ:CELG) for $74 billion in 2019, boosting its revenue as sales of its top-selling cancer drug Opdivo slowed due to stiff competition from Merck & Co Inc's Keytruda.
Bristol Myers also named Adam Lenkowsky as chief commercialization officer, replacing Boerner.
Bristol Myers is due to report first-quarter financial results on Thursday.
Pieniądz robi pieniądz a bieda robi jeszcze wiekszą biedę !!!
REKLAMA
Kto jest online
Użytkownicy przeglądający to forum: Obecnie na forum nie ma żadnego zarejestrowanego użytkownika i 99 gości